Back to search results

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

The ADNI4 study is looking for about 1,500 volunteers aged 55 to 90, including those with normal memory, mild cognitive impairment (MCI), or Alzheimer's disease (dementia). This study is observational, meaning it doesn't test new treatments but rather gathers information over time. Researchers will use special brain scans like Amyloid PET imaging (with Neuraceq, Amyvid, or NAV4694) and Tau PET imaging (with Tauvid or MK-6240) to understand how Alzheimer's disease progresses. The main goal is to enroll a diverse group of participants, especially those from underrepresented populations, over the next five years. This information will help improve future Alzheimer's research and clinical trials.

Study design
This is an observational study, meaning it doesn't test treatments. It aims to enroll about 1,500 participants across different stages of cognitive health.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study aims to measure the rate of enrollment of underrepresented populations over 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05617014

Alzheimer's Disease Neuroimaging Initiative 4

Enrolling by Invitation
Not specifiedAges 55–90Observational
University of Southern California
~1,500 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:NeuraceqAmyvidTauvidMK-6240NAV4694PI-2620

At a glance

Recruiting sites
0 of 65 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of enrollment of Underrepresented Populations (URPs)
Measured over 5 years

Conditions

Mild Cognitive Impairment
Alzheimer Disease
Dementia

Explore related trials

Alzheimer's DiseaseDementiaMild cognitive disorder

NCT05617014

Where you'd take part

This study runs at 65 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Albany Medical College

    Albany, New Yorkno site contact published

  • AllianceChicago

    Chicago, Illinoisno site contact published

  • Banner Alzheimer's Institute

    Phoenix, Arizonano site contact published

  • Banner Sun Health Research Institute

    Sun City, Arizonano site contact published

  • Barrow Neurological Institute

    Phoenix, Arizonano site contact published

  • Baylor College of Medicine

    Houston, Texasno site contact published

  • Beth Israel Deaconess Medical Center

    Boston, Massachusettsno site contact published

  • Boston University

    Boston, Massachusettsno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Michael Weiner, MD · STUDY_DIRECTOR · University of California, San Francisco
  • Paul Aisen, MD · PRINCIPAL_INVESTIGATOR · USC Alzheimer's Therapeutic Research Institute (ATRI)
  • Ronald Petersen, MD, PHD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Rate of enrollment of Underrepresented Populations (URPs)5 years

    The ADNI4 study aims to increased inclusion of underrepresented populations (URPs) to improve generalizability of results and advance our understanding of health disparities across URPs